false
OasisLMS
Catalog
SCCM Resource Library
Repurposing Host-Directed Therapeutics for COVID-1 ...
Repurposing Host-Directed Therapeutics for COVID-19
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The presentation discusses the exploration and trials involving tocilizumab, an IL-6 receptor inhibitor, for treating severe COVID-19, despite initial safety concerns. Three Roche-sponsored trials—Covactin, Impactin, and Aribdactin—produced mixed results. Impactin showed positive outcomes, reducing the progression to severe illness, albeit without impacting mortality. Notably, the larger U.K.-based Recovery trial demonstrated a significant mortality benefit with tocilizumab. Despite some safety data gaps in Recovery, subsequent meta-analyses confirmed tocilizumab's effectiveness while Roche trials assured its safety, leading to emergency use authorization. The speaker suggested pre-pandemic study infrastructure could improve response efficiency.
Asset Caption
90-Minute Session | Clinical Evidence for Host-Directed Therapeutics
Meta Tag
Content Type
Presentation
Membership Level
Professional
Membership Level
Select
Year
2024
Keywords
tocilizumab
COVID-19
clinical trials
mortality benefit
emergency use authorization
×
Please select your language
1
English